Dr. Carlo Gambacorti-Passerini
''Carlo Gambacorti-Passerini (born 1957) is an Italian oncologistand hematologist known for his contributions to cancer research. He is presently Professor of Internal Medicine at the University of Milan Bicoccain Italy and Director of the Clinical Research Unit at S. Gerardo Hospital, Monza, Italy. Previously he was Senior Investigator and Head of the Oncogenic Fusion Proteins Unit at the National Cancer Institute, Milan Italy (1990-2003), Professor of Oncology and Hematology at McGill University, Montreal, Canada (2004-2007).
His main scientific contribution relates to the preclinical and clinical development of imatinib.'' Extract from http://en.wikipedia.org/wiki/Carlo_Gambacorti-Passerini ''I played a key role in the clinical testing of Imatinib, an inhibitor of Bcr/Abl, an OFP which causes chronic myeloid leukemia. This work represents the first example of rational drug design, where a drug is developed to block an early event in the molecular pathogenesis of a human cancer.'' Extract from http://www.mcgill.ca/translational-research-cancer/researcher-biographies/gambacorti-passerini/ |
 |
Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia VIDEO
February 18, 2011, ecancerTV
ASH2010 - Bosutinib versus imatinib VIDEO
December 2010, Médecine Plus
February 18, 2011, ecancerTV
ASH2010 - Bosutinib versus imatinib VIDEO
December 2010, Médecine Plus
